SynthesisPLoS neglected tropical diseases2022
Estimates of Japanese Encephalitis mortality and morbidity: A systematic review and modeling analysis.
Synthesis in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Australian vertebrate hosts of Japanese encephalitis virus: a review of the evidence.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Pooled it
- Japanese Encephalitis Vaccine Decision Aid for Travelers: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Arboviral infections of the central nervous system: Mechanisms of invasion and long-term consequences.Journal of neurovirology · 2026Review
- Single-cell and bulk RNA sequencing reveal lncRNAs driving neuroimmune responses in Japanese encephalitis.BMC microbiology · 2026Article
- Post-acute sequelae after Nipah virus infection: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- A Bovine Cell Line Resistant to Japanese Encephalitis Virus Entry but Permissive to Post-Entry Replication.Viruses · 2026Article
- Complete Genome Sequences of Human Japanese Encephalitis Virus Genotype V Isolates in Korea Reveal Genotype-Specific Amino Acid Signatures.Pathogens (Basel, Switzerland) · 2025Article
- Thioester-Containing Protein TEP27 inInternational journal of molecular sciences · 2025Article
- Sequelae of viral CNS infections including outcomes, mechanisms, and knowledge gaps.Npj viruses · 2025Review
- Ecological suitability of Japanese encephalitis virus in Australia: A modelling analysis of vector-host transmission dynamics to potential spillover in humans.PLoS neglected tropical diseases · 2025Article
- Zoonotic disease outbreaks reported under India'sThe Lancet regional health. Southeast Asia · 2025Article
- A rare case of symmetric quadriplegia in a patient with Japanese encephalitis: a case report.Annals of medicine and surgery (2012) · 2025Article
- The alarming spread of Japanese encephalitis: A growing public health concern.Open veterinary journal · 2025Review
- Scoping Review of Japanese Encephalitis Virus Transmission Models.Transboundary and emerging diseases · 2025Article
- Article
- Impact of vaccination against Japanese encephalitis in endemic countries.PLoS neglected tropical diseases · 2024Article
- The Role of Wild Boar as Host of Japanese Encephalitis Virus in the Absence of Domestic Pigs.Viruses · 2024Article
- Informing an investment case for Japanese encephalitis vaccine introduction in Bangladesh.Science advances · 2024Article
- Article
- Australian vertebrate hosts of Japanese encephalitis virus; a review of the evidence.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundJapanese Encephalitis (JE) is known for its high case fatality ratio (CFR) and long-term neurological sequelae. Over the years, efforts in JE treatment and control might change the JE fatality risk. However, previous estimates were from 10 years ago, using data from cases in the 10 years before this. Estimating JE disease severity is challenging because data come from countries with different JE surveillance systems, diagnostic methods, and study designs. Without precise and timely JE disease severity estimates, there is continued uncertainty about the JE disease burden and the effect of JE vaccination. METHODOLOGY: We performed a systematic review to collate age-stratified JE fatality and morbidity data. We used a stepwise model selection with BIC as the selection criteria to identify JE CFR drivers. We used stacked regression, to predict country-specific JE CFR from 1961 to 2030. JE morbidity estimates were grouped from similar study designs to estimate the proportion of JE survivors with long-term neurological sequelae. PRINCIPAL
findingsWe included 82 and 50 peer-reviewed journal articles published as of March 06 2021 for JE fatality and morbidity with 22 articles in both analyses. Results suggested overall JE CFR estimates of 26% (95% CI 22, 30) in 1961-1979, 20% (95% CI 17, 24) in 1980-1999, 14% (95% CI 11, 17) in 2000-2018, and 14% (95% CI 11, 17) in 2019-2030. Holding other variables constant, we found that JE fatality risk decreased over time (OR: 0.965; 95% CI: 0.947-0.983). Younger JE cases had a slightly higher JE fatality risk (OR: 1.012; 95% CI: 1.003-1.021). The odds of JE fatality in countries with JE vaccination is 0.802 (90% CI: 0.653-0.994; 95% CI: 0.62-1.033) times lower than the odds in countries without JE vaccination. Ten percentage increase in the percentage of rural population to the total population was associated with 15.35% (95% CI: 7.71, 22.57) decrease in JE fatality odds. Ten percentage increase in population growth rate is associated with 3.71% (90% CI: 0.23, 7.18; 95% CI: -0.4, 8.15) increase in JE fatality odds. Adjusting for the effect of year, rural population percent, age of JE cases, and population growth rate, we estimated that there was a higher odds of JE fatality in India compared to China. (OR: 5.46, 95% CI: 3.61-8.31). Using the prediction model we found that, in 2000-2018, Brunei, Pakistan, and Timor-Leste were predicted to have the highest JE CFR of 20%. Bangladesh, Guam, Pakistan, Philippines, and Vietnam had projected JE CFR over 20% for after 2018, whereas the projected JE CFRs were below 10% in China, Indonesia, Cambodia, Myanmar, Malaysia, and Thailand. For disability, we estimated that 36% (min-max 0-85) JE patients recovered fully at hospital discharge. One year after hospital discharge, 46% (min-max 0%-97%) JE survivors were estimated to live normally but 49% (min-max 3% - 86%)till had neurological sequelae.
conclusionJE CFR estimates were lower than 20% after 2000. Our study provides an updated estimation of CFR and proportion of JE cases with long-term neurological sequelae that could help to refine cost-benefit assessment for JE control and elimination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.